Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT05028166
Individual Patient Compassionate Use of Mirdametinib
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
View on ClinicalTrials.gov
Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-05-08
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
Mirdametinib (MEK Inhibitor)
Patients will receive oral mirdametinib.